Latran, 4 mg 10 pcs

Latran is an antiemetic, antiabstinence.

Pharmacodynamics

A selective antagonist of 5-HT₃ receptors (serotonin). Inhibits the emergence of gagging effect by blockade of 5-HT₃ receptors at the neuronal level of both the central and peripheral nervous system. It has anxiolytic activity and does not cause sedation, impaired coordination of movements or decreased activity and performance. It smoothes somatic and psychopathological symptoms during alcohol withdrawal syndrome.

Pharmacokinetics

Injection C_max in plasma is reached within 10 minutes; after oral administration, about 1.5 h. The distribution of ondansetron is the same when administered orally, intravenously and volumetrically. Absolute bioavailability is about 60%. Binding to plasma proteins is 70-76%. It is metabolized in the liver. Less than 5% of the drug is excreted unchanged in the urine. After oral intake and parenteral administration T_1/2 is about 3 hours, in elderly patients it can be up to 5 hours, and in severe hepatic insufficiency 15-32 hours. In renal impairment (creatinine1/2 Cl increases by 4-5 h, but this increase is not clinically significant.

Indications

Active ingredient

Composition

1 tablet contains:

The active ingredient:

ondansetron hydrochloride dihydrate (in terms of base)4 mg;

Associates:

MCC;

Silicon dioxide colloid (aerosil);

Potato starch;

Magnesium stearate;

Composition of the shell:

hydroxypropylcellulose;

tween 80 (polysorbate);

Tropeolin O;

Castor oil.

How to take, the dosage

Intravenously, intramuscularly, orally.

Cytostatic therapy: The choice of dosing regimen is determined by the emetogenicity of the antitumor therapy. For adults, the daily dose is usually 8-32 mg; the following regimens are recommended:

In moderate emetogenic chemotherapy or radiotherapy

Highly emetogenic chemotherapy

Interaction

Because ondansetron is metabolized by the liver enzyme system (cytochrome P450), caution is required when used together:

– with enzymatic inducers of P450 (CYP2D6 and CYP3A) (barbiturates, carbamazepine, carisoprodol, glutethimide, griseofulvin, nitrous oxide, papaverine, phenylbutazone, phenytoin and probably other hydantoins, rifampicin, tolbutamide);

– with P450 enzyme inhibitors (CYP2D6 and CYP3A) (allopurinol, macrolide antibiotics, antidepressants – MAO inhibitors, chloramphenicol, cimetidine, estrogen-containing oral contraceptives, diltiazem, disulfiram, erythromycin, valproic acid, sodium valproate, fluconazole, fluoroquinolones, isoniazid, ketoconazole, lovastatin, metronidazole, omeprazole, propranololol, quinidine, quinine, verapamil).

Special Instructions

Sensitivity reactions with Latran® may occur in patients previously observed for similar reactions with other selective 5-HT3 receptor antagonists.

Patients with signs of bowel obstruction after using the drug require regular monitoring because ondansetron may cause constipation.

The infusion solution should be prepared immediately prior to use. If necessary, the prepared infusion solution may be stored for a maximum of 24 h at 2-8 °C prior to use.

Protection from light is not required during infusion: the diluted infusion solution remains stable for at least 24 h in natural light or normal lighting.

Contraindications

Side effects

Nervous system disorders: headache, dizziness, spontaneous motor disorders and convulsions.

Cardiovascular system: chest pain, in some cases with ST-segment depression, bradycardia, arrhythmias, arterial hypotension.

Gastrointestinal system disorders: hiccups, dry mouth, diarrhea, constipation, and sometimes asymptomatic transient elevation of serum aminotransferases.

Allergic reactions: urticaria, bronchospasm, laryngospasm, angioedema, anaphylaxis.

Others: local reactions (pain, burning and redness at the injection site), blood rush to the face, fever, temporary visual acuity impairment, hypokalemia.

Overdose

In cases of suspected overdose, symptomatic therapy is indicated.

In cases of overdose, the use of ipecacuana is not recommended, as it is unlikely that this drug will be effective during the anti-emetic effect of Latran®.

A specific antidote is not known.

Similarities